Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Igor  Puzanov

Igor Puzanov, M.D., M.S.C.I, F.A.C.P.

Associate Professor of Medicine (Hematology/Oncology)
Associate Director of Phase I Drug Development
Director, Melanoma Clinical Research
Clinical Director, Renal Cancer
Medical Oncologist

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-343-6653
  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
    Clinic Fax
    615-343-7602
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    2220 Pierce Avenue
    777 Preston Research Building
    Nashville, TN 37232-6307
Profile

Dr. Puzanov is an Associate Professor of Medicine in the Division of Hematology-Oncology. Dr. Puzanov joined our faculty in July of 2005 after completing a three-year fellowship in Hematology-Oncology at Vanderbilt University Medical Center. He completed his residency in Internal Medicine at University of Texas Southwestern Medical Center at Dallas and was board certified in 2001.
Read more...

Dr. Puzanov is an Associate Professor of Medicine in the Division of Hematology-Oncology. Dr. Puzanov joined our faculty in July of 2005 after completing a three-year fellowship in Hematology-Oncology at Vanderbilt University Medical Center. He completed his residency in Internal Medicine at University of Texas Southwestern Medical Center at Dallas and was board certified in 2001. Prior to that, he received his M.D. degree from Charles University in Prague. Dr. Puzanov is an Associate Director of the Phase I Program, Director of Melanoma Clinical Research and Clinical Director of Renal Cell Carcinoma. In these roles, he is responsible for the development of new innovative therapies for patients with melanoma and RCC as well as co-leadership of a Phase I Program with emphasis on the genomic data integration and immunotherapy concepts. He leads collaborations with the cardiology department to study cardiotoxicity of anti-VEGF therapies for cancer and with Radiation Oncology department on the synergistic effects between radiation and immunotherapies.

Education
  • Charles University, Prague, Czechoslovakia, M.D., 1991
  • Internship, Internal Medicine and Surgery, Faculty Hospital Royal Vineyards
  • Residency/Internship, Internal Medicine, UT Southwestern Medical Center
  • Fellowship in Medical Oncology and Hematology, Vanderbilt University
  • Master of Science in Clinical Investigation, Vanderbilt University
Publications
  • Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2015 Feb 2/15/2015; 21(4): 701-11. PMID: 25212606, PII: 1078-0432.CCR-14-0303, DOI: 10.1158/1078-0432.CCR-14-0303, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25212606.
  • Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer [print-electronic]. 2014 Sep 9/1/2014; 120(17): 2684-93. PMID: 24802654, PMCID: PMC4142676, DOI: 10.1002/cncr.28767, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24802654.
  • Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol [print-electronic]. 2014 Aug; 15(9): 954-65. PMID: 25037139, PII: S1470-2045(14)70301-8, DOI: 10.1016/S1470-2045(14)70301-8, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25037139.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol [print-electronic]. 2014 Apr 4/1/2014; 32(10): 1020-30. PMID: 24590637, PII: JCO.2013.53.0105, DOI: 10.1200/JCO.2013.53.0105, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24590637.
  • Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2: 2. PMID: 24829759, PMCID: PMC4019894, PII: 2051-1426-2-2, DOI: 10.1186/2051-1426-2-2, ISSN: 2051-1426.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24829759.
  • Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 2013 Dec 12/15/2013; 19(24): 6696-702. PMID: 24345920, PMCID: PMC3880773, PII: 19/24/6696, DOI: 10.1158/1078-0432.CCR-13-1746, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24345920.
  • Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J. Immunother. 2013 Nov; 36(9): 490-5. PMID: 24145360, PII: 00002371-201311000-00005, DOI: 10.1097/CJI.0000000000000003, ISSN: 1537-4513.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24145360.
  • Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol [print-electronic]. 2013 May 5/10/2013; 31(14): 1767-74. PMID: 23569304, PII: JCO.2012.44.7888, DOI: 10.1200/JCO.2012.44.7888, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23569304.
  • Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA. ¿-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Clin. Cancer Res [print-electronic]. 2013 Feb 2/1/2013; 19(3): 721-30. PMID: 23251007, PII: 1078-0432.CCR-12-2529, DOI: 10.1158/1078-0432.CCR-12-2529, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23251007.
  • Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013; 11: 137. PMID: 23731854, PMCID: PMC3681569, PII: 1479-5876-11-137, DOI: 10.1186/1479-5876-11-137, ISSN: 1479-5876.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23731854.
  • Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer [print-electronic]. 2012 Dec 12/15/2012; 118(24): 6055-62. PMID: 22674198, PMCID: PMC3934426, DOI: 10.1002/cncr.27668, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22674198.
  • Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T, . Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann. Oncol [print-electronic]. 2012 Dec; 23(12): 3137-43. PMID: 22700990, PII: mds145, DOI: 10.1093/annonc/mds145, ISSN: 1569-8041.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22700990.
  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med [print-electronic]. 2012 Nov; 367(18): 1694-703. PMID: 23020132, PMCID: PMC3549295, DOI: 10.1056/NEJMoa1210093, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23020132.
  • Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol [print-electronic]. 2012 Nov; 13(11): 1087-95. PMID: 23051966, PII: S1470-2045(12)70431-X, DOI: 10.1016/S1470-2045(12)70431-X, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23051966.
  • Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2012 Jun 6/15/2012; 18(12): 3414-27. PMID: 22510349, PII: 1078-0432.CCR-11-3369, DOI: 10.1158/1078-0432.CCR-11-3369, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22510349.
  • McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J. Clin. Oncol [print-electronic]. 2012 May 5/10/2012; 30(14): 1628-34. PMID: 22454415, PII: JCO.2011.39.1938, DOI: 10.1200/JCO.2011.39.1938, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22454415.
  • Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol [print-electronic]. 2012 May; 13(5): 459-65. PMID: 22456429, PII: S1470-2045(12)70090-6, DOI: 10.1016/S1470-2045(12)70090-6, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22456429.
  • Patrawala S, Puzanov I. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol. 2012 May; 8(5): 509-23. PMID: 22646766, DOI: 10.2217/fon.12.31, ISSN: 1744-8301.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22646766.
  • Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012 Feb 2/23/2012; 366(8): 707-14. PMID: 22356324, PMCID: PMC3724515, DOI: 10.1056/NEJMoa1112302, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22356324.
  • Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012 Jan 1/19/2012; 366(3): 207-15. PMID: 22256804, PMCID: PMC3724537, DOI: 10.1056/NEJMoa1105358, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22256804.
  • Arenbergerová M, Puzanov I. [BRAF mutation: a novel approach in targeted melanoma therapy]. Klin Onkol. 2012; 25(5): 323-8. PMID: 23102192, PII: 38972, ISSN: 0862-495X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23102192.
  • Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. Oncologist [print-electronic]. 2012; 17(12): 1534-40. PMID: 22622146, PMCID: PMC3528385, PII: theoncologist.2011-0422, DOI: 10.1634/theoncologist.2011-0422, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22622146.
  • Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I, Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck [print-electronic]. 2011 Dec; 33(12): 1804-8. PMID: 20652976, PMCID: PMC3111896, DOI: 10.1002/hed.21478, ISSN: 1097-0347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20652976.
  • Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin. Cancer Res [print-electronic]. 2011 Jun 6/1/2011; 17(11): 3794-802. PMID: 21346148, PMCID: PMC3107910, PII: 1078-0432.CCR-10-2056, DOI: 10.1158/1078-0432.CCR-10-2056, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21346148.
  • Puzanov I, Burnett P, Flaherty KT. Biological challenges of BRAF inhibitor therapy. Mol Oncol [print-electronic]. 2011 Apr; 5(2): 116-23. PMID: 21393075, PII: S1574-7891(11)00021-4, DOI: 10.1016/j.molonc.2011.01.005, ISSN: 1878-0261.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21393075.
  • Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 9/30/2010; 467(7315): 596-9. PMID: 20823850, PMCID: PMC2948082, PII: nature09454, DOI: 10.1038/nature09454, ISSN: 1476-4687.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20823850.
  • Flaherty KT, Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem. Pharmacol [print-electronic]. 2010 Sep 9/1/2010; 80(5): 638-46. PMID: 20382128, PII: S0006-2952(10)00250-9, DOI: 10.1016/j.bcp.2010.04.005, ISSN: 1873-2968.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20382128.
  • Puzanov I, Flaherty KT. Targeted molecular therapy in melanoma. Semin Cutan Med Surg. 2010 Sep; 29(3): 196-201. PMID: 21051014, PII: S1085-5629(10)00080-5, DOI: 10.1016/j.sder.2010.06.005, ISSN: 1558-0768.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21051014.
  • Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010 Aug 8/26/2010; 363(9): 809-19. PMID: 20818844, PMCID: PMC3724529, DOI: 10.1056/NEJMoa1002011, ISSN: 1533-4406.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20818844.
  • Shepherd C, Puzanov I, Sosman JA. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep. 2010 May; 12(3): 146-52. PMID: 20425073, DOI: 10.1007/s11912-010-0095-2, ISSN: 1534-6269.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20425073.
  • Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin. Cancer Res [print-electronic]. 2010 Jan 1/1/2010; 16(1): 348-57. PMID: 20028756, PMCID: PMC3205975, PII: 1078-0432.CCR-09-2087, DOI: 10.1158/1078-0432.CCR-09-2087, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20028756.
  • Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol [print-electronic]. 2009 Dec 12/1/2009; 27(34): 5800-7. PMID: 19786654, PII: JCO.2009.23.6745, DOI: 10.1200/JCO.2009.23.6745, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19786654.
  • Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer. 2009 May 5/15/2009; 115(10 Suppl): 2368-75. PMID: 19402058, DOI: 10.1002/cncr.24234, ISSN: 0008-543X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19402058.
  • Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, Hachey DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom. 2008 Jan; 43(1): 42-52. PMID: 17683023, DOI: 10.1002/jms.1268, ISSN: 1076-5174.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17683023.
  • Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 2007 Jan 1/15/2007; 13(2 Pt 2): 764s-769s. PMID: 17255307, PII: 13/2/764s, DOI: 10.1158/1078-0432.CCR-06-1975, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17255307.
  • Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res. 2006 Apr 4/1/2006; 12(7 Pt 2): 2376s-2383s. PMID: 16609062, PII: 12/7/2376s, DOI: 10.1158/1078-0432.CCR-05-2558, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16609062.
  • Gruber HE, Puzanov IJ, Bennett M, Kumar V, Gordon B. Alterations in osteoclast morphology following long-term 17beta-estradiol administration in the mouse. BMC Cell Biol [print-electronic]. 2001; 2: 3. PMID: 11231877, PMCID: PMC29068, ISSN: 1471-2121.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11231877.
  • Sivakumar PV, George T, Puzanov IJ, Williams NS, Stepp S, Liu J, Schatzle J, Lai WC, Bennett M, Kumar V. Hybrid resistance by mouse NK cells in vitro. Methods Mol. Biol. 2000; 121: 73-9. PMID: 10818718, DOI: 10.1385/1-59259-044-6:73, ISSN: 1064-3745.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10818718.
  • Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Bennett M, Kumar V. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J. Immunol. 1999 Sep 9/1/1999; 163(5): 2648-56. PMID: 10453005, PII: ji_v163n5p2648, ISSN: 0022-1767.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10453005.
  • Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Schatzle JD, Bennett M, Kumar V. Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunol. Rev. 1998 Oct; 165: 47-61. PMID: 9850851, ISSN: 0105-2896.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9850851.
  • Sivakumar PV, Puzanov I, Williams NS, Bennett M, Kumar V. Ontogeny and differentiation of murine natural killer cells and their receptors. Curr. Top. Microbiol. Immunol. 1998; 230: 161-90. PMID: 9586356, ISSN: 0070-217X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9586356.
  • Sivakumar PV, Williams NS, Puzanov IJ, Schatzle JD, Bennett M, Kumar V. Development of self-recognition systems in natural killer cells. Adv. Exp. Med. Biol. 1998; 452: 1-12. PMID: 9889953, ISSN: 0065-2598.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9889953.
  • Williams NS, Moore TA, Schatzle JD, Puzanov IJ, Sivakumar PV, Zlotnik A, Bennett M, Kumar V. Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J. Exp. Med. 1997 Nov 11/3/1997; 186(9): 1609-14. PMID: 9348320, PMCID: PMC2199105, ISSN: 0022-1007.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9348320.
  • Puzanov IJ, Williams NS, Schatzle J, Sivakumar PV, Bennett M, Kumar V. Ontogeny of NK cells and the bone marrow microenvironment: where does IL15 fit in?. Res. Immunol. 1997 Mar; 148(3): 195-201. PMID: 9255874, PII: S0923249497842253, ISSN: 0923-2494.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9255874.
  • Puzanov IJ, Bennett M, Kumar V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J. Immunol. 1996 Nov 11/15/1996; 157(10): 4282-5. PMID: 8906800, ISSN: 0022-1767.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8906800.